Organogenesis Holdings Inc. (NASDAQ:ORGO) headquartered in Canton, will host a conference call for the investment community to discuss the 2Q20 earnings result on 10th August 2020 at 5:00 PM Eastern Time.
Those interested in listening to the conference call live via the Internet can visit organogenesis.com
Earnings Expectation
Organogenesis Holdings Inc. is reporting second quarter earnings results on Monday 10th August 2020, after market close. The consensus estimates from Thomson Reuters are loss of $ 0.22 per share. For the full year, analysts predict revenues of $ 244.24 million, while looking forward to loss of $ 0.69 per share.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 273.00 million ~ $ 277.00 million
Click Here For More Historical Outlooks Of Organogenesis Holdings Inc.
Organogenesis Holdings Inc., a regenerative medicine company, focuses on the development, manufacture, and commercialization of solutions for the advanced wound care, and surgical and sports medicine markets primarily in the United States. The companys advanced wound care products include Apligraf for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft for treating DFUs; PuraPly AM to address biofilm across a range of wound types; and Affinity and NuShield to address various wound sizes and types. Its surgical and sports medicine products comprise ReNu for in-office joint and tendon applications; NuCel for bony fusion in the spine and extremities; NuShield and Affinity for surgical applications in targeted soft tissue repairs; and PuraPly AM for the surgical treatment of open wounds.
